Here are the S-1 registration statements from Actuate Therapeutics, Inc. (ACTU) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow ACTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACTU filings page.
Actuate Therapeutics, Inc. (ACTU) proposes a primary offering of 40,000,000 common shares and 20,000,000 purchase warrants exercisable for 20,000,000 shares. It also offers pre-funded warrants for up to 40,000,000 shares in lieu of common shares when a purchase would exceed 4.99% ownership (or 9.99% if elected); shares issuable on warrant exercise are also covered. A 45-day underwriter option covers up to 6,000,000 additional shares and 3,000,000 warrants. Sales cannot begin until the registration statement is effective.
The assumed price is $1.00 per two shares and one warrant; final pricing will be set with the underwriter and may be discounted. Proceeds are intended for working capital and general corporate purposes. At the assumed $0.50 per-share price, the prospectus estimates immediate dilution of approximately $0.20 per share. Projected post-offering shares outstanding are 64,013,577, assuming full pre-funded warrant exercise, no purchase warrant exercise, and no over-allotment.
Actuate is a clinical-stage biopharmaceutical company developing elraglusib; more than 500 patients have received it. Its 286-patient Phase 2 pancreatic cancer study met its primary endpoint, with statistically significant median overall survival improvement versus GnP alone. Nasdaq notified Actuate that its market value was below the $50 million minimum market value of listed securities; the company has until January 11, 2027, to regain compliance.
Actuate Therapeutics, Inc. is offering 65,000,000 shares of common stock at an assumed $0.6437 per share; the final price will be set with the underwriter and may be discounted. Sales cannot begin before the registration statement is effective. The underwriter may buy up to 9,750,000 additional shares under an option exercisable for 45 days after closing. Expected shares outstanding after the offering are 89,013,577 without the option. Actuate expects to use net proceeds for working capital and general corporate purposes; stated immediate dilution is approximately $0.1937 per share.
Cash and cash equivalents were $4,425,841 and working capital was $942,745 as of June 30, 2026; Actuate says it will need additional financing after the offering. The company reported that it did not meet Nasdaq Global Market’s $50 million minimum market value of listed securities requirement for the 30-business-day period ended July 14, 2026. It has until January 11, 2027, to regain compliance, including meeting the threshold for at least 10 consecutive business days; the notice does not currently affect its listing.
Actuate is developing elraglusib for difficult-to-treat cancers and reports treating over 500 patients in Phase 1 and Phase 2 studies. Its 286-patient Phase 2 metastatic pancreatic cancer study met its primary endpoint, with a statistically significant median overall survival improvement for elraglusib plus gemcitabine/nab-paclitaxel versus that chemotherapy alone. The FDA cleared the oral formulation for a Phase 1/2 study.
Actuate Therapeutics, Inc. is registering a primary offering of 50,000,000 shares of common stock at an assumed $0.819 per share. The final price may be at a discount, and sales cannot begin until the registration statement is effective. The underwriter has a 45-day option to purchase up to 7,500,000 additional shares. Actuate expects to use the net proceeds for working capital and general corporate purposes.
Actuate is a clinical-stage biopharmaceutical company developing elraglusib, a GSK-3β inhibitor. It reports that its randomized Phase 2 study in 286 patients with metastatic pancreatic ductal adenocarcinoma met its primary endpoint, with a statistically significant improvement in median overall survival for elraglusib plus gemcitabine/nab-paclitaxel versus that regimen alone. The FDA cleared a Phase 1/2 study of the oral formulation.
As of June 30, 2026, cash and cash equivalents were $4,425,841 and working capital was $942,745. Actuate had not met Nasdaq Global Market’s $50 million minimum market value of listed securities requirement for the 30-business-day period ended July 14, 2026; it has until January 11, 2027, to regain compliance.